108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
司库奇尤单抗联合手术治疗腋臭的疗效及安全性分析：一项中国真实世界回顾性研究
Authors Liu X, Yuan C, Kang Y, Zhang J, Li Y, Wang R, Ding C, Zhang J, Xing W
Received 30 July 2025
Accepted for publication 10 October 2025
Published 22 October 2025 Volume 2025:18 Pages 14493—14502
DOI https://doi.org/10.2147/JIR.S554170
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Anish R. Maskey
Xiaojie Liu,1,* Chuanjian Yuan,2,* Yuan Kang,3,* Jun Zhang,1 Yibo Li,1 Ruiqi Wang,1 Chen Ding,1 Junling Zhang,1,* Weibin Xing1,*
1Department of Dermatology, Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 3National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weibin Xing, Email 15922246725@163.com
Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder. The IL-17A antagonist secukinumab has shown promising efficacy in international clinical trials; however, real-world evidence from China remains limited. This study evaluates the effectiveness and safety of secukinumab combined with surgical intervention for treating severe HS in a Chinese cohort.
Patients and Methods: A retrospective analysis of 21patients with HS admitted to our hospital from May 2023 to August 2024 was conducted. The patients received combination therapy consisting of secukinumab and palliative surgery. The primary efficacy endpoint was the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR50) at week 16. Secondary endpoints included HiSCR50 response rates at weeks 32 and 48, changes in the International Hidradenitis Suppurativa Severity Score System (IHS4), Visual Analog Scale (VAS) scores for pain, Dermatology Life Quality Index (DLQI) scores, and the incidence of adverse events at weeks 16, 32, and 48.
Results: At week 16, the HiSCR50 response rate was 76.2% (16/21), accompanied by a significant 71.3% reduction in the IHS4 score from baseline (P < 0.001). Both the DLQI and VAS scores demonstrated notable decreases of 44.2% and 43.7% (P < 0.001 for both). By week 48, sustained improvements were observed in HiSCR50 response, IHS4 score, DLQI, and VAS scores, with reduction rates of 75.2%, 57.1%, and 65.3%. Only one patient reported mild eczema, and no serious adverse events were documented.
Conclusion: Secukinumab in combination with surgical intervention rapidly and significantly improves clinical symptoms, quality of life, and pain levels in Chinese patients with moderate-to-severe HS, while demonstrating a favorable safety profile. This combined therapeutic approach may represent a novel treatment option for severe HS; however, further validation through large-scale, multicenter studies is warranted.
Keywords: Secukinumab, Hidradenitis Suppurativa, Inflammatory Diseases, Surgery
1Department of Dermatology, Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 3National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weibin Xing, Email 15922246725@163.com
Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder. The IL-17A antagonist secukinumab has shown promising efficacy in international clinical trials; however, real-world evidence from China remains limited. This study evaluates the effectiveness and safety of secukinumab combined with surgical intervention for treating severe HS in a Chinese cohort.
Patients and Methods: A retrospective analysis of 21patients with HS admitted to our hospital from May 2023 to August 2024 was conducted. The patients received combination therapy consisting of secukinumab and palliative surgery. The primary efficacy endpoint was the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR50) at week 16. Secondary endpoints included HiSCR50 response rates at weeks 32 and 48, changes in the International Hidradenitis Suppurativa Severity Score System (IHS4), Visual Analog Scale (VAS) scores for pain, Dermatology Life Quality Index (DLQI) scores, and the incidence of adverse events at weeks 16, 32, and 48.
Results: At week 16, the HiSCR50 response rate was 76.2% (16/21), accompanied by a significant 71.3% reduction in the IHS4 score from baseline (P < 0.001). Both the DLQI and VAS scores demonstrated notable decreases of 44.2% and 43.7% (P < 0.001 for both). By week 48, sustained improvements were observed in HiSCR50 response, IHS4 score, DLQI, and VAS scores, with reduction rates of 75.2%, 57.1%, and 65.3%. Only one patient reported mild eczema, and no serious adverse events were documented.
Conclusion: Secukinumab in combination with surgical intervention rapidly and significantly improves clinical symptoms, quality of life, and pain levels in Chinese patients with moderate-to-severe HS, while demonstrating a favorable safety profile. This combined therapeutic approach may represent a novel treatment option for severe HS; however, further validation through large-scale, multicenter studies is warranted.
Keywords: Secukinumab, Hidradenitis Suppurativa, Inflammatory Diseases, Surgery